Zenas BioPharma (ZBIO) Depreciation & Amortization (CF) (2023 - 2026)
Zenas BioPharma (ZBIO) recorded quarterly Depreciation & Amortization (CF) of $6000.0 in Q1 2026, down 40.0% quarter-over-quarter from $10000.0 in Q4 2025, and down 73.91% on a YoY basis from $23000.0 in Q1 2025.
Zenas BioPharma (ZBIO) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Zenas BioPharma's Depreciation & Amortization (CF) history runs 4 years deep, the most recent figure standing at $6000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 73.91% year-over-year to $6000.0; the TTM figure through Mar 2026 stood at $39000.0 (down 69.29% YoY), while the FY2025 annual figure was $56000.0, down 59.12% from the prior year.
- Depreciation & Amortization (CF) was $6000.0 for Q1 2026 at Zenas BioPharma, down from $10000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $36000.0 in Q3 2024 to a low of $6000.0 in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $22900.0 across 4 years, with a median of $26500.0 in 2023.
- The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) rose 10.0% in 2024, then sank 73.91% in 2026.
- A 4-year view of Depreciation & Amortization (CF) shows it stood at $30000.0 in 2023, then grew by 10.0% to $33000.0 in 2024, then plunged by 69.7% to $10000.0 in 2025, then slumped by 40.0% to $6000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $6000.0 (Q1 2026), $10000.0 (Q4 2025), and $11000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Zenas BioPharma | 1.10 Bn | 379.43 Mn | - | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Sep 30, 2025 | 11,000.00 |
| Sep 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Dec 31, 2024 | 33,000.00 |
| Dec 31, 2024 | 33,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Jun 30, 2024 | 35,000.00 |
| Jun 30, 2024 | 35,000.00 |
| Mar 31, 2024 | 33,000.00 |
| Mar 31, 2024 | 33,000.00 |
| Dec 31, 2023 | 30,000.00 |
| Dec 31, 2023 | 30,000.00 |